Free Trial
→ This Tiny Sub-$1 Gold-Silver Royalty Stock Is Ready to Run (From Digest Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$76.99
$74.59
$10.11
▼
$77.20
$1.63B2.621.86 million shsN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
$135.46
-3.0%		$97.82
$41.50
▼
$166.48
$6.24B2.831.54 million shs701,268 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$79.94
+1.4%		$77.82
$35.20
▼
$82.98
$6.15B0.04536,731 shs1.48 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$298.50
+1.2%		$292.25
$175.89
▼
$326.63
$5.88B1.14270,584 shs332,107 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
0.00%0.00%0.00%+57.57%+494.98%
GRAIL, Inc. stock logo
GRAL
GRAIL
-3.04%+2.15%+78.50%+86.53%+79.37%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+1.40%+1.51%+6.37%+25.00%+105.71%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
+1.19%+1.19%+7.77%-1.61%+62.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$76.99
$74.59
$10.11
▼
$77.20
$1.63B2.621.86 million shsN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
$135.46
-3.0%		$97.82
$41.50
▼
$166.48
$6.24B2.831.54 million shs701,268 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$79.94
+1.4%		$77.82
$35.20
▼
$82.98
$6.15B0.04536,731 shs1.48 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$298.50
+1.2%		$292.25
$175.89
▼
$326.63
$5.88B1.14270,584 shs332,107 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
0.00%0.00%0.00%+57.57%+494.98%
GRAIL, Inc. stock logo
GRAL
GRAIL
-3.04%+2.15%+78.50%+86.53%+79.37%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+1.40%+1.51%+6.37%+25.00%+105.71%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
+1.19%+1.19%+7.77%-1.61%+62.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.00
Hold$71.67-6.91% Downside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$119.80-11.56% Downside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2.89
Moderate Buy$93.1416.52% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$337.8913.20% Upside

Current Analyst Ratings Breakdown

Latest FBRX, GRAL, KNSA, and LGND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/13/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$88.00 ➝ $180.00
10/12/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$60.00 ➝ $120.00
10/8/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C+) ➝ Buy (B-)
10/2/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$105.00 ➝ $175.00
10/1/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$75.00 ➝ $155.00
9/30/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$87.00
9/28/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$80.00 ➝ $150.00
9/25/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$65.00 ➝ $100.00
9/25/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$345.00
9/24/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/24/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$358.00
(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.66 per shareN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M41.12N/AN/A$66.13 per share2.05
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$677.56M9.20$0.80 per share99.32$7.44 per share10.74
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$290.54M20.48$7.95 per share37.57$51.68 per share5.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$69.38M-$4.65N/AN/AN/AN/A-94.82%-77.68%11/13/2026 (Estimated)
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%11/11/2026 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$59.01M$0.9782.4138.62N/A9.59%13.65%10.09%10/27/2026 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$124.45M$9.3531.9335.752.3867.88%20.06%11.68%11/5/2026 (Estimated)

Latest FBRX, GRAL, KNSA, and LGND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.5017N/AN/AN/A$44.21 millionN/A
11/5/2026Q3 2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$2.26N/AN/AN/A$77.95 millionN/A
10/27/2026Q3 2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.3722N/AN/AN/A$260.22 millionN/A
8/12/2026Q2 2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.9950-$0.97+$0.0250-$0.97N/AN/A
8/6/2026Q2 2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.97$2.37+$0.40$2.22$61.30 million$63.69 million
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
7/28/2026Q2 2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.2995$0.30+$0.0005$0.30$226.49 million$243.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
10.01
10.01
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.90
3.49
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
1.16
31.18
30.96

Institutional Ownership

CompanyInstitutional Ownership
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
53.95%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%

Insider Ownership

CompanyInsider Ownership
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
4.40%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
51.98%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
5.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
521.23 million20.30 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.67 million43.85 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
36678.02 million37.47 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4719.94 million18.82 millionOptionable

Recent News About These Companies

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
October 15 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/15/3381492/0/en/ligand-to-report-third-quarter-2026-financial-results-on-october-29-2026.html
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Crosses Above 200 Day Moving Average - Should You Sell?
October 14 at 2:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-ligand-pharmaceuticals-nasdaq-lgnd-stock-crosses-above-200-day-moving-average-should-you-sell-2026-10-14/
Ligand Pharmaceuticals (NASDAQ:LGND) Stock: Insider Andrew Reardon Sells 5,000 Shares
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098771
Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,520,350.00 in Stock
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-ligand-pharmaceuticals-nasdaq-lgnd-insider-sells-152035000-in-stock-2026-10-06/
Ligand Pharmaceuticals (NASDAQ:LGND) Share Price Breaks Above 200 Day Moving Average - Time to Sell?
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090284
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Breaks Above 200-Day Moving Average - Here's What Happened
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-ligand-pharmaceuticals-nasdaq-lgnd-stock-breaks-above-200-day-moving-average-heres-what-happened-2026-10-06/
Ligand Pharmaceuticals stock expands royalty pipeline with USD 47.00 million deal
September 30, 2026  |  ad-hoc-news.deA
Hogan Lovells Cadwalader advises Ligand on financing agreement with AvenCell Therapeutics
September 30, 2026  |  legaldesire.comL
Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ligand-pharmaceuticals-lgnd-using-avencell-042527182.html
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Has Consensus Price Target of $337.89
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-ligand-pharmaceuticals-incorporated-nasdaq-lgnd-stock-has-consensus-price-target-of-33789-2026-09-28/
Ligand Joins with AvenCell, Shares Down
September 25, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/24105/Ligand-Joins-with-AvenCell-Shares-Down
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Ligand Pharma (LGND) and Compass Therapeutics (CMPX)
September 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CMPX/pressreleases/4773213/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-ligand-pharma-lgnd-and-compass-therapeutics-cmpx/
Barclays Begins Coverage on Ligand Pharmaceuticals (NASDAQ:LGND)
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-barclays-begins-coverage-on-ligand-pharmaceuticals-nasdaq-lgnd-2026-09-25/
HC Wainwright Reiterates Buy Rating for Ligand Pharmaceuticals (NASDAQ:LGND)
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hc-wainwright-reiterates-buy-rating-for-ligand-pharmaceuticals-nasdaq-lgnd-2026-09-24/
Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy
September 24, 2026  |  rttnews.comhttps://www.rttnews.com/3693652/ligand-commits-upto-47-mln-to-avencell-cancer-cell-therapy.aspx
Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ligand-pharmaceuticals-invests-47-million-113521771.html
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368190/0/en/ligand-and-avencell-therapeutics-enter-financing-agreement-to-advance-pipeline-of-next-generation-car-t-therapies-for-up-to-47-million.html
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $397.00 Price Target at Citigroup
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-ligand-pharmaceuticals-nasdaq-lgnd-given-new-39700-price-target-at-citigroup-2026-09-23/
Sydnexis sells EMEA royalty rights to Ligand for $23 million
September 23, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Sydnexis+sells+EMEA+royalty+rights+to+Ligand+for+%2423+million/27088789.html
Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug
September 23, 2026  |  rttnews.comhttps://www.rttnews.com/3692945/ligand-buys-royalty-rights-in-santen-s-ryjunea-eye-drug.aspx
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
September 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ligand-acquires-royalty-milestone-interest-110000068.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$135.46 -4.24 (-3.04%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$137.00 +1.54 (+1.14%)
As of 05:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$79.94 +1.10 (+1.40%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$80.00 +0.06 (+0.08%)
As of 04:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$298.50 +3.51 (+1.19%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$298.02 -0.48 (-0.16%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas